Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · IEX Real-Time Price · USD
45.32
-3.04 (-6.29%)
At close: Aug 11, 2022 4:00 PM
45.98
+0.66 (1.46%)
Pre-market: Aug 12, 2022 7:18 AM EDT
-6.29%
Market Cap 1.81B
Revenue (ttm) 8.82M
Net Income (ttm) -149.93M
Shares Out 39.91M
EPS (ttm) -3.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,143,591
Open 48.36
Previous Close 48.36
Day's Range 44.67 - 48.82
52-Week Range 19.38 - 48.82
Beta 1.92
Analysts Buy
Price Target 85.05 (+87.7%)
Earnings Date Aug 9, 2022

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbe... [Read more...]

Industry Pharmaceuticals
IPO Date Nov 19, 2015
CEO Herriot Tabuteau
Employees 108
Stock Exchange NASDAQ
Ticker Symbol AXSM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is 85.05, which is an increase of 87.67% from the latest price.

Price Target
$85.05
(87.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Why Axsome Therapeutics Topped the Market Today

The company records nearly $9 million in quarterly sales from its recently acquired drug.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

7 Small-Cap Growth Stocks With 1,000% Upside Potential

Small-cap growth stocks with 1,000% upside potential is our topic for today. They are usually young companies with a market capitalization (cap) between $300 million and $2 billion.

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time

3 Beaten-Down Stocks That Could Soar in the Second Half of 2022

Each of these stocks is ready for a rebound.

Other symbols: MRVINVCR

7 Biotech Stocks to Buy for Q3

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on Inv...

What's Winning in 2022? 3 Stocks That Are Doing Fine

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

Other symbols: IMCRTAK

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...

Los Angeles, California--(Newsfile Corp. - July 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, I...

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Beha...

NEW YORK , July 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the...

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in A...

NEW YORK , July 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of it...

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcom...

New York, New York--(Newsfile Corp. - July 11, 2022) - Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsu...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome The...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors w...

AXSM FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Lo...

New York, New York--(Newsfile Corp. - July 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between De...

DEADLINE TOMORROW ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...

Los Angeles, California--(Newsfile Corp. - July 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, I...

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, ...

NEW YORK , July 11, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...

Los Angeles, California--(Newsfile Corp. - July 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, In...

AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022

NEW YORK , July 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM). To rece...

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,...

Los Angeles, California--(Newsfile Corp. - July 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, In...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit an...

NEW YORK , July 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc.. Shareholders who purchased shares of AXSM during the class period lis...

AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit

Shareholders with $500,000 losses or more are encouraged to contact the firm.   LOS ANGELES , July 5, 2022 /PRNewswire/ -- The Law Offices of Frank R.

3 Growth Stocks That Could Make You Richer in the Second Half of 2022

These stocks appear to have good chances of delivering solid gains by year-end.

Other symbols: NVCR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, In...

New York, New York--(Newsfile Corp. - July 3, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and ...

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Other symbols: ADAPGTHX

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Befo...

NEW YORK , June 30, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 20...